Friday, August 04, 2017 2:02:05 PM
I first heard of ONVO on a famous long-running Canadian CBC Nature and Science TV documentary series called "The Nature of Things", with Dr. David Suzuki (geneticist and environmentalist).
He visited an ONVO university lab in the U.S., where indeed he and the university lab scientist were discussing exactly that option - the ability to order replacement parts for the human body in the future through ONVO.
I was so struck by the fact that a serious Canadian scientist and documentary-maker would mention a commercial public American start-up company, that I immediately investigated ONVO. Suzuki is not a flighty or commercial kind of guy.
Have had most of my joints replaced already (working on the last ones), so my friends and family already call me the "bionic woman", but if I needed a new heart, kidney or liver........another matter altogether.
I wonder if a single-payer system like we have in Canada would help the development of game-changing medical developments like ONVO is working on. Might be cheaper to give all us "baby-boomers" new hearts, rather than look after us for years in long-term care. And the open-heart surgery required might be faster, easier and cheaper than what is done now, and more long-term effective, with better outcomes and fewer complications.
Recent ONVO News
- Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo • GlobeNewswire Inc. • 04/15/2024 12:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/09/2024 05:15:07 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/08/2024 09:56:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/08/2024 09:05:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:05:17 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/26/2024 10:09:03 PM
- Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress • GlobeNewswire Inc. • 01/25/2024 01:05:00 PM
- Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress • GlobeNewswire Inc. • 01/09/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:05:09 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/22/2023 11:05:02 AM
- Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results • GlobeNewswire Inc. • 12/06/2023 01:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/01/2023 09:07:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:41:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:40:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:37:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:34:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:32:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/15/2023 09:41:04 PM
- CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan • GlobeNewswire Inc. • 11/13/2023 01:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:10:34 PM
- Organovo Highlights FXR314 Combination Therapy Potential and Plan • GlobeNewswire Inc. • 11/08/2023 01:05:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 12:05:08 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 09/22/2023 08:05:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/13/2023 09:06:56 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM